LEO Pharma announces FDA approval of Adbry (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate to severe atopic dermatitis

Leo Pharma

28 December 2021 - Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022.

LEO Pharma announced today that the U.S. FDA has approved Adbry (tralokinumab) for the treatment of moderate to severe atopic dermatitis in adults 18 years or older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Read Leo Pharma press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , US